

AD \_\_\_\_\_

Award Number: DAMD17-01-1-0496

TITLE: Identification of Genomic Determinants of Response of  
Metastatic Disease to Taxol and Adriamycin

PRINCIPAL INVESTIGATOR: Joe W. Gray, Ph.D.

CONTRACTING ORGANIZATION: University of California, San Francisco  
San Francisco, California 94143-0962

REPORT DATE: October 2002

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030604 043

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE October 2002	3. REPORT TYPE AND DATES COVERED Final (17 Sep 01 - 16 Sep 02)
----------------------------------	--------------------------------	---

4. TITLE AND SUBTITLE Identification of Genomic Determinants of Response of Metastatic Disease to Taxol and Adriamycin	5. FUNDING NUMBERS DAMD17-01-1-0496
---	--

6. AUTHOR(S) : Joe W. Gray, Ph.D.
--------------------------------------

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of California, San Francisco San Francisco, California 94143-0962  Email: jgray@cc.ucsf.edu	8. PERFORMING ORGANIZATION REPORT NUMBER
---	--

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012	10. SPONSORING / MONITORING AGENCY REPORT NUMBER
---	--

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited	12b. DISTRIBUTION CODE
---	------------------------

13. ABSTRACT (Maximum 200 Words)  
  
none provided

14. SUBJECT TERMS: drug response, genetic predisposition	15. NUMBER OF PAGES 7
	16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited
---	--	---	---

## Table of Contents

Cover.....	1
SF 298.....	2
Introduction.....	4
Body.....	5-6
Key Research Accomplishments.....	6
Reportable Outcomes.....	7
Conclusions.....	7
References.....	7
Appendices.....	N/A

## FINAL REPORT DAMD17-01-1-0496

Principal investigator: Joe W. Gray, PhD

**INTRODUCTION:** Human breast cancer genesis and progression is caused by the aberrant function of genes that positively and negatively regulate aspects of cell proliferation, apoptosis, genome stability, angiogenesis, invasion and metastasis(1). Discovery and functional assessment of these genes is critical for understanding the biology of cancer, and for clinical applications including early cancer detection and improved prediction of cancer risk, disease course and response to therapy. Although many different events can cause aberrant gene function, chromosomal aberrations resulting in changes in gene dosage or structure play important roles. Interestingly, there is remarkable variability in the degree to which tumor genomes are aberrant at the chromosomal level. Some tumors have few chromosomal aberrations, while in others there may be dozens. Furthermore, the aberration spectrum typically differs substantially among clinically similar tumors. It is likely that many of these aberrations are accumulated by chance during the proliferation of cells with substantial genome instability and do not contribute to substantially to the tumor phenotype. However, some specific aberrations occur frequently and very likely do affect function. Extensive catalogues of recurrent abnormalities in a wide range of solid tumors have been compiled from cytogenetic(2) and CGH studies(3). These analyses show that tumors that arise in different anatomical sites differ significantly in recurrent aberration composition, as do histologically distinct tumors that arise in the same anatomic location(4-6). The spectrum of aberrations also varies with the genetic makeup of the patient. For example, recurrent aberrations in tumors that arise in individuals with *BRCA1* mutations differ from those in tumors from *BRCA2* carriers and from those in tumors that arise spontaneously(7). The influence of genetic background on tumorigenesis and recurrent aberration spectrum also is clear in analyses of murine tumor models(8, 9).

Experimentally, chromosomal aberrations are important because they are distinctive and can be readily detected and mapped using an increasing number of complementary technologies. Thus, their discovery and genomic localization provides important clues about the locations of genes that are important in breast cancer etiology. We hypothesize that analyses of breast tumors using array CGH techniques developed by us will reveal genomic changes that are associated with novel genes that influence cancer susceptibility and/or that predict response to therapy. Thus, our long-term plan is to apply array CGH to analysis tumors from patients treated with Herceptin to identify patients that are most likely to respond and to tumors from patients at high familial risk of developing breast cancer but not carriers of *BRCA1* or *BRCA2* mutations in order to facilitate additional cancer susceptibility gene.

## **BODY:**

Most pathological specimens that are now available from Herceptin treated and familial cancer patients are formalin-fixed and paraffin-embedded prior to histological evaluation. Unfortunately, extraction of high quality DNA suitable for array CGH from such tissues has been difficult, presumably because of damage and DNA-protein cross-linking that occurs during the fixation and embedding (10, 11). Some of the parameters that influence the degradation of DNA at the stage of tissue fixation are known, for example, the age of specimens, the fixative, and the duration of fixation (12, 13). In practice, these parameters are highly variable between hospitals and institutions. Thus, the goal of this project was optimize techniques for nucleic acid extraction from diverse paraffin-blocks to obtain DNA for the DNA microarray analysis. Paraffin blocks assessed during these studies were from the UCSF Cancer Center, the NSABP and several laboratories participating in an International Breast Cancer Susceptibility Gene Identification Consortium.

Tissue sections were cut at 30  $\mu\text{m}$ , collected on clean untreated glass slides, deparaffinized twice with xylene and rehydrated with ethanol (95%, 75%, and 50%) and water followed by light staining with 0.1% methyl green. Five  $\mu\text{m}$  sections were cut before and after the 30  $\mu\text{m}$  sections, deparaffinized and stained with hematoxylin and eosin and used for histological control to identify the area of interests. A pathologist selected areas of specific histological interest on the stained sections. Microdissection was performed under dissecting microscope with a surgical scalpel blade. The procedure consisted of the removal of unwanted (nontumorous) cells by gentle scraping and the collection of microdissected area of interests into 1.5 ml eppendorf tube for DNA extraction. We evaluated several methods reported in the literature to improve the quality and quantity of DNA extraction from paraffin-block including thorough de-waxing of the paraffin and digestion of the deparaffinized tissue with proteinase K. In addition, we tested several approaches to reverse DNA-protein cross-linking.

Overall, we analyzed forty-two paraffin embedded samples. Five of the cases were "large" blocks so that we were able to apply all extraction protocols in parallel. In general, the DNA extraction protocol using the Promega "Wizard Genomic DNA Extraction Kit" modified with (a) EDTA added in the lysis buffer to prevent degradation and (b) extended proteinase K digestion produced the most reliable results. On the other hand, pretreatment with "target antigen retrieval" using citrate buffer plus heat at 95C as recommended for immunohistochemistry produced degraded DNA. Lowering the temperature to 80C and the duration of heating to 20 min yielded higher quality DNA but the approach was still inferior to the "Promega" method.

We were able to obtain DNA that was adequate for CGH analysis in 28 cases. Figure 1 shows a typical array CGH profile for one of these cases. We were not able to extract DNA of adequate quality from 14 cases using any of the extraction protocols.




Figure 1. Array CGH analysis of a paraffin embedded breast cancer sample. Relative copy number is displayed with chromosome 1pter to the left and chromosome 22qter and X to the right. The vertical lines indicate chromosome boundaries. Selected genes are indicated in the figure.

In general, DNA extraction was straightforward using the Promega Wizard kit when the samples were fixed and embedded in academic laboratories where fixation and embedding are rigorously controlled. However, we were much less successful in analyzing samples from European community hospitals where the preparation quality may have been less carefully controlled. This lack of success was sufficiently high that we were forced to abandon our efforts to apply array CGH to familial breast cancer samples collected from European community hospitals.

#### KEY RESEARCH ACCOMPLISHMENTS:

- We evaluated several DNA extraction protocols in an effort to find one that would be generally applicable to formal fixed, paraffin embedded samples from diverse sources.
- We found that our procedure based on the use of the Promega Wizard kit was satisfactory for samples prepared in academic laboratories where preparation quality control was high.

## REPORTABLE OUTCOMES:

None

## CONCLUSIONS:

Fixation and paraffin embedding procedures used to archive breast tumor samples dramatically influence subsequent efforts to extract DNA for array CGH analyses. Rigorous quality control of the fixation procedure is particularly critical. Extraction of high quality DNA is straightforward from properly prepared samples and impossible (at least using the methods evaluated in this study) from samples that have been improperly prepared. Guidelines for preparation of formal fixed, paraffin embedded samples are needed to insure the utility of these samples in future research projects.

## REFERENCES:

1. D. Hanahan, R. A. Weinberg, *Cell* **100**, 57-70 (Jan 7, 2000).
2. F. Mitelman, B. Johansson, F. Mertens, <http://cgap.nci.nih.gov/Chromosomes/Mitelman> (2002).
3. S. Knuutila, K. Autio, Y. Aalto, *Am J Pathol* **157**, 689. (2000).
4. J. S. Smith *et al.*, *Oncogene* **18**, 4144-52 (Jul 15, 1999).
5. H. Lassus *et al.*, *Lab Invest* **81**, 517-26 (Apr, 2001).
6. K. Gunther *et al.*, *J Pathol* **193**, 40-7 (Jan, 2001).
7. M. Tirkkonen *et al.*, *Genes Chromosomes Cancer* **24**, 56-61 (Jan, 1999).
8. A. Balmain, *Cell* **108**, 145-52 (Jan 25, 2002).
9. G. Hodgson *et al.*, *Nat Genet* **29**, 459-64 (Dec, 2001).
10. P. Kiene, K. Milde-Langosch, M. Runkel, K. Schulz, T. Loning, *Virchows Arch A Pathol Anat Histopathol* **420**, 269-73 (1992).
11. J. S. Park *et al.*, *Mod Pathol* **4**, 667-70 (Sep, 1991).
12. C. E. Greer, C. M. Wheeler, M. M. Manos, *PCR Methods Appl* **3**, S113-22 (Jun, 1994).
13. L. Dubeau, L. A. Chandler, J. R. Gralow, P. W. Nichols, P. A. Jones, *Cancer Res* **46**, 2964-9 (Jun, 1986).

Personnel paid from this grant:

Kuo, Wen-Lin